Live Breaking News & Updates on Lambers heerspink

Novartis atrasentan Phase III data show clinically

Novartis atrasentan Phase III data show clinically
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United-states , Switzerland , Stockholm , Sweden , America , Lambers-heerspink , Sloan-simpson , Michael-meo , Satoshi-sugimoto , Jonathan-graham , Imke-kappes , Marlena-abdinoor

Novartis Pharma AG: Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs.

Stockholm , Sweden , Switzerland , United-states , America , Sloan-simpson , Nicole-zinsli-somm , Lambers-heerspink , Jonathan-graham , Satoshi-sugimoto , Parag-mahanti , Marlena-abdinoor

Novartis Pharma AG: Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis Pharma AG: Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Switzerland , United-states , America , American , Michael-meo , Nicole-zinsli-somm , Ihre-chancen , Marlena-abdinoor , Indiens-wirtschaft , Richard-jarvis , Jonathan-graham , Lambers-heerspink